ClinicalTrials.gg
RecruitingNCT06647524Updated Oct 9, 2025

Pilot fMRI Studies of Aging-Related Effects of THC

A Phase 2 interventional study of THC and Placebo in THC, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by Yale University · Phase 2, Interventional, and Basic science

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to begin investigating acute impairment of various forms of memory and learning by Tetrahydrocannabinol (THC) in cannabis (CNB) compared to placebo, in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design in young to middle-aged adults.

Read the detailed description

Tasks tapping each of the major cognitive memory-related domains will be performed in the MRI scanner, to reveal the relevant underlying circuitry and its disruption by drug using functional MRI.

On an initial Screening Visit, regular or novice cannabis (CNB) users will undergo informed consent, clinical assessment (to fully evaluate inclusion/exclusion criteria), cognitive/personality assessment, and a structural MRI scan.

At each assessment, subjects will provide subjectively-rated CNB intoxication using a verbal analog scale, complete 2 fMRI paradigms within \~1.5 hours: a) Card Guessing task and b) Complex Working Memory Span, and complete the computer-based Effort Expenditure for Reward Task within \~2 hours. These tests will be counterbalanced across subjects and sessions to minimize order and fatigue effects. Breaks will be standardized in a private environment and snacks/meals provided. Bathroom visits given as needed. Subjects will be supervised at all times by study staff and vital signs monitored. On assessment days, participants will remain at the Olin NRC until they report no subjective intoxication, and are observed by study staff to be no longer objectively intoxicated, then use taxi or Uber transportation home.

02

Conditions studied

  • THC

Browse trials for

Keywords

  • Memory Impairment
  • Learning Impairment
03

In context

Memory Disorders

373 studies on the registry are indexed under Memory Disorders; 67 are open to participants now.

This study's planned enrollment of 10 is below the median of 72 across 298 interventional studies indexed under Memory Disorders.

Browse Memory Disorders studies →

Lead sponsor

Yale University is the lead sponsor of 1,770 studies on the registry; 294 are open to participants now.

Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CNB use within past 2 years and felt "high" when used.
  • Able to read, speak, and understand English.
  • Able and willing to provide written , and willing to commit to the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Current marijuana tolerance, desire to cut down, or cravings to use during periods of abstinence.
  • Positive screen for drug or alcohol (except CNB) on test day will result in rescheduling the appointment
  • History of adverse effects with CNB
  • CNB users who are abstaining
  • IQ \<80 on the Wechsler Abbreviated Scale of Intelligence
  • Inability to comprehend written instructions using the WRAT 4 reading achievement test
  • Pregnant, breastfeeding, and ineffective methods
  • Unable or unsafe to have an MRI
  • Serious medical, neuro-ophthalmological, or neurological illness (e.g. cancer, seizure disorders, encephalopathy
  • History of head trauma with loss of consciousness > 30 minutes or concussion lasting 30 days
  • Focal brain lesion seen on structural MRI
  • Any medical/neurological condition that could compromise neurocognitive performance (e.g. epilepsy, multiple sclerosis, fetal alcohol syndrome)
  • Anyone deemed unsafe to study personnel for any reason
  • Hearing loss such that subject cannot hear sounds at the levels (dB) or pitches (Hz) to be used in the study
  • Significant pain and/or reduced mobility in the arms
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    THC then Placebo

    Participants in this arm will receive THC then placebo in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design. (Participants randomized to receive THC in the first session will receive placebo at the 2nd session.) Sessions will be scheduled at least one week apart. Tasks tapping each of the major cognitive memory-related domains will be performed in the MRI scanner, to reveal the relevant underlying circuitry and its disruption by drug using functional MRI.

    Drug: THC · Drug: Placebo

  • Placebo comparator
    Placebo then THC

    Participants in this arm will receive placebo then THC in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design. (Participants randomized to receive placebo in the first session will receive THC at the 2nd session.) Sessions will be scheduled at least one week apart. Tasks tapping each of the major cognitive memory-related domains will be performed in the MRI scanner, to reveal the relevant underlying circuitry and its disruption by drug using functional MRI.

    Drug: THC · Drug: Placebo

Interventions

  • DrugTHC

    Participants will be administered 0.5g of vaporized THC cannabis (12% THC cannabis)

  • DrugPlacebo

    Participants will be administered identical plant material from which all THC has been removed by solvent extraction.

06

What researchers measure

Primary outcomes

  1. The Complex Working Memory Span (CWMS) Task- Items Recalled

    CWMS Task assesses immediate plus delayed recall and working memory by assessing working memory capacity by presenting a list of stimuli to be recalled while simultaneously performing a secondary task. This task uses a fully crossed design which includes both same-domain CWMS conditions (e.g. verbal storage combined with verbal processing) as well as cross-domain CWMS conditions (e.g., verbal storage combined with spatial processing). Mean number of total items recalled.

    Time frame: At sessions 1 and 2 while under fMRI, immediately post drug administration

  2. The Complex Working Memory Span (CWMS) Task- fMRI measure

    CWMS Task assesses immediate plus delayed recall and working memory by assessing working memory capacity by presenting a list of stimuli to be recalled while simultaneously performing a secondary task. This task uses a fully crossed design which includes both same-domain CWMS conditions (e.g. verbal storage combined with verbal processing) as well as cross-domain CWMS conditions (e.g., verbal storage combined with spatial processing). BOLD signal Infrontal lobe.

    Time frame: At sessions 1 and 2 while under fMRI, immediately post drug administration

  3. The Effort Expenditure for Reward Task (EEfRT)

    (EEfRT) is an out-of-scanner measure of effort-based decision-making that utilizes a choice model ("easy-task" or "hard-task") in response to varying monetary rewards. This task assesses motivation in relation to reward magnitude, implicating the activation or suppression of dopaminergic pathways in the nucleus accumbens (NAcc). Percentage of hard-task choices across all levels of probability is calculated from all hard choices. Lower percentages of hard task choices indicate decreased motivation.

    Time frame: At sessions 1 and 2 immediately post drug administration

  4. The Card-Guessing fMRI task

    The Card-Guessing fMRI task (28) will be used to investigate the effects of acute THC intoxication on decision-making, risk-taking, and reward processing. This task involves various trial types including win, loss, disappointment, and relief, to assess how THC affects reward expectancy and prediction error processing during decision-making presented as the fMRI blood-oxygen-level-dependent (BOLD) signal in response to card-guessing task.

    Time frame: At sessions 1 and 2 while under fMRI, immediately post drug administration

  5. The Zibrio SmartScale

    The Zibrio SmartScale aggregates balance data to create a "Balance Score", which assesses postural sway with respect to balance ability and fall risk. Total score range 1 and 10. A lower score indicates a higher risk of falling.

    Time frame: At sessions 1 and 2 while under fMRI, immediately post drug administration

07

Study locations

1 of 1 sites recruiting
  • Olin Neuropsychiatric Research Center at Hartford Healthcare
    Hartford, Connecticut 06106, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 17, 2024
StartActual
Jul 1, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Oct 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06647524
Lead sponsor
Yale University
Collaborators
Biopharmaceutical Research Company, Bloom Labs Cannabis Solutions
Responsible party
Godfrey Pearlson (Professor of Psychiatry and of Neuroscience, Yale University) — Principal investigator
First posted
Oct 17, 2024
Start date
Jul 1, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 9, 2025

Study contacts

Godfrey Pearlson, MD
Contact
godfrey.pearlson@yale.edu
860-305-8921
Ariana Caruso
Contact
ariana.caruso2@hhchealth.org
Godfrey Pearlson, M.D
principal investigator · Founding Director, Olin Neuropsychiatry Center; Yale University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion